| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8940757 | European Urology Oncology | 2018 | 6 Pages |
Abstract
There is variability in prostate cancer outcomes after surgery, depending on the definition of pretreatment high-risk disease used. Clinical stage T3 and high Gleason score were most strongly associated with prostate cancer-specific mortality and overall mortality.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Matthew Mossanen, Kenneth G. Nepple, Robert L. 3rd, Gerald L. Androile, Dorina Kallogjeri, Eric A. Klein, Andrew J. Stephenson, Adam S. Kibel,